Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice g...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamat, Ashish M., Bellmunt, Joaquim, Galsky, Matthew D., Konety, Badrinath R., Lamm, Donald L., Langham, David, Lee, Cheryl T., Milowsky, Matthew I., O’Donnell, Michael A., O’Donnell, Peter H., Petrylak, Daniel P., Sharma, Padmanee, Skinner, Eila C., Sonpavde, Guru, Taylor, John A., Abraham, Prasanth, Rosenberg, Jonathan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557323/
https://www.ncbi.nlm.nih.gov/pubmed/28807024
http://dx.doi.org/10.1186/s40425-017-0271-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557323/
https://www.ncbi.nlm.nih.gov/pubmed/28807024
http://dx.doi.org/10.1186/s40425-017-0271-0

Ejemplares similares